Coinbase Global, Inc. (COIN) closed at $251.59 in the latest trading session, marking a +0.48% move from the prior day. The stock lagged the S&P 500’s daily gain of 0.83%.
Prior to today’s trading, shares of the company had lost 3.03% over the past month. This has lagged the Finance sector’s loss of 1.34% and was narrower than the S&P 500’s loss of 3.68% in that time.
Investors will be hoping for strength from COIN as it approaches its next earnings release.
Any recent changes to analyst estimates for COIN should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.41% lower. COIN currently has a Zacks Rank of #3 (Hold).
In terms of valuation, COIN is currently trading at a Forward P/E ratio of 18.28. This valuation marks a discount compared to its industry’s average Forward P/E of 23.71.
The Securities and Exchanges industry is part of the Finance sector. This group has a Zacks Industry Rank of 65, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.